Attached files
| file | filename |
|---|---|
| EX-99.1 - EX-99.1 - SUPERNUS PHARMACEUTICALS, INC. | supn-20130702ex9910f520b.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 27, 2013
Supernus Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
|
Delaware |
|
(State or other jurisdiction of Incorporation) |
|
0-50440 |
|
20-2590184 |
|
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
|
|
|
|
|
|
|
1550 East Gude Drive, Rockville MD |
|
20850 |
|
|
(Address of principal executive offices) |
|
(Zip Code) |
|
Registrant’s telephone number, including area code: (301) 838-2500
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events
On June 27, 2013, Supernus Pharmaceuticals, Inc. (“Supernus”) issued a press release announcing that on June 26, 2013 it received a Paragraph IV Notice Letter from Watson Laboratories, Inc. ("Watson") advising
1454701.2
Supernus of the filing by Watson of an Abbreviated New Drug Application seeking approval for oxcarbazepine extended-release tablets. Supernus is currently reviewing the details of this Notice Letter and intends to vigorously enforce its intellectual property rights relating to Oxtellar XR. The product is currently protected by two issued patents that are listed in the FDA’s Orange Book. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
The following document is furnished as an Exhibit pursuant to Item 8.01 hereof:
Exhibit 99.1 – Press Release Dated June 27, 2013.
_________________________________________________________________________________________
1454701.2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
SUPERNUS PHARMACEUTICALS, INC.
DATED: July 2, 2013By: /s/ Gregory S. Patrick
Gregory S. Patrick
Vice-President and Chief Financial Officer
1454701.2
EXHIBIT INDEX
NumberDescription
99.1Press Release dated June 27, 2013. Attached
1454701.2